Go Deep
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,833 | -2.1 | 1.14 | 0.02 | 255.23 |
| Oct 2026 | 21,058 | -1.9 | 1.05 | 0.02 | 236.42 |
| Oct 2026 | 20,939 | -2.2 | 1.10 | 0.02 | 245.95 |
| Oct 2026 | 21,010 | -2.0 | 1.07 | 0.02 | 239.63 |
| Oct 2026 | 20,927 | -2.0 | 1.10 | 0.02 | 246.52 |
| Oct 2026 | 20,596 | -2.2 | 1.22 | 0.02 | 273.07 |
| Oct 2026 | 20,667 | -2.2 | 1.20 | 0.02 | 266.72 |
| Oct 2026 | 20,407 | -2.4 | 1.29 | 0.02 | 286.95 |
SAB Biotherapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -22,491,000.0 | -18,868,885.0 | -16,860,743.0 | 45,445,469.0 |
| EPS | -0.3 | -0.3 | — | 0.5 |
SAB Biotherapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | 13,273,683.0 | -34,105,309.0 | -42,193,786.0 | -18,740,804.0 | — |
| EPS | 0.2 | -3.7 | -7.6 | -4.3 | — |
SAB Biotherapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 172,809,969.0 | 44,195,469.0 | 83,941,253.0 | 50,904,927.0 | — |
| Total Liabilities | 21,315,594.0 | 18,225,893.0 | 26,641,812.0 | 19,846,785.0 | — |
| Total Equity | 151,494,375.0 | 25,969,576.0 | 57,299,441.0 | 31,058,142.0 | — |
Owes vs Owns
SAB Biotherapeutics, Inc. owed $0.10 for every $1 it owned in Jun 2026, down from $0.39 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.10× | 0.12× | 0.41× | 0.32× | 0.39× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
SAB Biotherapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 55.9%Receivables 0.5%Fixed assets (tangible) 11.2%Long-term investments 27.1%Other assets 5.2%
How it's funded — Dec 2025
Short-term debt 0.6%Long-term debt 2.9%Payables 1.8%Other liabilities 7.1%Shareholders' equity 87.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 96.6 | 20.8 | 56.6 | 15.0 |
| Receivables | 0.9 | 0.1 | 0.0 | 5.6 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 19.4 | 19.9 | 24.7 | 28.3 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 46.9 | 0.0 | 0.0 | 0.0 |
| Other assets | 9.0 | 3.5 | 2.7 | 2.0 |
| Liabilities & equity | ||||
| Short-term debt | 1.0 | 0.3 | 1.1 | 0.8 |
| Long-term debt | 5.0 | 3.9 | 4.1 | 0.5 |
| Payables | 3.1 | 1.7 | 0.9 | 3.7 |
| Other liabilities | 12.2 | 12.4 | 20.6 | 14.9 |
| Shareholders' equity | 151.5 | 26.0 | 57.3 | 31.1 |
| Net tangible assets | 151.5 | 26.0 | 57.3 | 31.1 |
SAB Biotherapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -44,775,111.0 | -34,292,009.0 | -25,119,405.0 | -23,459,511.0 | — |
| Investing Activities | -121,706,130.0 | -11,962,267.0 | -152,704.0 | -2,090,024.0 | — |
| Financing Activities | 168,299,452.0 | -1,172,626.0 | 66,773,137.0 | 1,051,411.0 | — |